4.7 Review

Left Main Percutaneous Coronary Intervention

期刊

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 60, 期 17, 页码 1605-1613

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2012.01.085

关键词

left main; percutaneous coronary intervention; stent

资金

  1. Boston Scientific
  2. Abbott
  3. Medtronic
  4. AstraZeneca
  5. Daiichi-Sankyo/Eli Lilly Co.

向作者/读者索取更多资源

The introduction of drug-eluting stents and advances in catheter techniques have led to increasing acceptance of percutaneous coronary intervention (PCI) as a viable alternative to coronary artery bypass graft (CABG) for unprotected left main disease. Current guidelines state that it is reasonable to consider unprotected left main PCI in patients with low to intermediate anatomic complexity who are at increased surgical risk. Data from randomized trials involving patients who are candidates for either treatment strategy provide novel insight into the relative safety and efficacy of PCI for this lesion subset. Herein, we review the current data comparing PCI with CABG for left main disease, summarize recent guideline recommendations, and provide an update on technical considerations that may optimize clinical outcomes in left main PCI. (J Am Coll Cardiol 2012;60:1605-13) (c) 2012 by the American College of Cardiology Foundation

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据